Clinical

Dataset Information

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors


ABSTRACT: This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

DISEASE(S): Metastatic Solid Tumor,Melanoma,Colorectal Cancer,Non-small Cell Lung Cancer,Advanced Solid Tumor,Pancreatic Ductal Adenocarcinoma,Neoplasms

PROVIDER: 2377928 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR